Is Mounjaro a good option for people with type 2 diabetes?

What the SURPASS trial data actually showed, and why it matters here

The question of whether Mounjaro is good for diabetics has a concrete evidence base to draw from. The SURPASS clinical programme enrolled thousands of adults with type 2 diabetes across multiple trials, testing tirzepatide against placebo and against established treatments including insulin glargine, insulin degludec, and semaglutide. At the 15mg maintenance dose, tirzepatide reduced HbA1c by around 2.0–2.4 percentage points from baseline, among the largest reductions seen in any approved oral or injectable diabetes medicine. Crucially, that blood-sugar improvement came alongside average body-weight reductions of up to around 12–15kg, which matters because weight loss itself improves insulin sensitivity.

NICE's appraisal of tirzepatide, published in December 2024 (TA1026), reviewed this evidence base in detail. The committee concluded that tirzepatide offers a clinically meaningful benefit over alternatives for the populations studied. The NHS patient information page for tirzepatide also notes the dual licence: it is approved both for type 2 diabetes and for weight management in the UK, making it somewhat unusual among injectable treatments.

What the trials cannot tell you is how Mounjaro will interact with your specific diabetes medicines, your kidney function, or your cardiovascular history. That requires an actual clinical assessment, not a trial average.

The dual licence: how Mounjaro sits differently from other GLP-1 treatments in diabetes

Mounjaro is a dual GIP and GLP-1 receptor agonist. Most other injectable weight and diabetes medicines activate only the GLP-1 pathway. The addition of GIP receptor activity appears to amplify both the glucose-lowering and appetite-suppressing effects, which is why the HbA1c and weight results from SURPASS tended to exceed those from earlier GLP-1 monotherapy trials.

This distinction has practical implications. People with type 2 diabetes who have not achieved adequate glucose control on metformin alone, or who need to lose weight as part of managing their condition, represent the population for whom the evidence is strongest. If you are already on a GLP-1 treatment and your prescriber is considering a switch, the comparison between tirzepatide and semaglutide is worth examining, the evidence on tirzepatide specifically for type 2 diabetes covers those head-to-head data in more depth.

One thing worth raising with your prescriber: Mounjaro lowers blood sugar partly by stimulating insulin release in a glucose-dependent way, which means the risk of hypoglycaemia is relatively low on its own. The picture changes if you are also taking a sulphonylurea or insulin. Your prescriber may adjust those doses when starting tirzepatide.

What's still uncertain, and who genuinely needs to be careful

The evidence on long-term cardiovascular outcomes specifically for tirzepatide in type 2 diabetes is still accumulating. The SURPASS-CVOT trial is ongoing. This is not unusual for newer medicines, and it does not mean the medicine is unsafe, it means the full outcomes picture will sharpen over the next few years. The MHRA continues to monitor tirzepatide under its Black Triangle (▼) scheme, meaning healthcare professionals are asked to report any suspected side effects.

There are also specific situations where Mounjaro is not suitable or requires very careful prescriber oversight. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) is a contraindication. A history of pancreatitis also warrants discussion before starting. Kidney function matters too, severe impairment may affect suitability. And for women of childbearing age who have type 2 diabetes and are planning a pregnancy, or who are already pregnant or breastfeeding, Mounjaro is not recommended. Our page on Mounjaro and trying to conceive covers the contraception and conception guidance in detail.

Our clinical team reviews every consultation individually. If you have questions specific to your diabetes regimen or want to understand whether tirzepatide could work alongside your current treatment, that is exactly what the consultation is for.

Getting access: what a diabetic patient should know about the private route

If you have type 2 diabetes and are considering Mounjaro privately, our page on Mounjaro for diabetics explains what the private route involves in full, including what a prescriber will assess and how the process works. This is not a form submitted to an algorithm. At nume, a GPhC-registered Independent Prescriber reads your consultation the same day and makes a clinical judgement, approval only follows if the medicine is clinically appropriate for you.

It is worth noting that timing occasionally catches people out: if you are planning to start treatment, orders placed before midday on a working day are dispatched the same afternoon once approved, arriving the next working day. That matters if you are thinking about this before a holiday or across a bank holiday weekend, check the calendar rather than assuming. If you are still weighing up whether the medicine is right for your situation, our page covering whether diabetics can take Mounjaro sets out the eligibility considerations in detail. Details of current private treatment options and consultation are on our treatments page, and the FAQs answer common questions about the process. If you have a question our prescribers do not cover in the consultation, our team is available seven days a week.

For a fuller picture of the medicine itself (mechanism, dosing schedule, and how to start) the Mounjaro overview is the right starting point.